Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vaccine therapy plus sargramostim following chemotherapy in Stage III/IV non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL [Phase 1]
Phase 1 clinical trial update on safety and efficacy of betalutin with rituximab in follicular lymphoma, completed with posted results in 20…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]
Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were post…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) [Phase 2]
Phase 2 safety trial evaluating lisocabtagene maraleucel (JCAR017) for relapsed/refractory B-cell non-Hodgkin lymphoma in the outpatient set…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell ly…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update for CD19-targeted CAR T cells in relapsed/refractory non-Hodgkin lymphoma, including DLBCL and follicular lymphoma, wit…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Phase III Copanlisib in Rituximab-refractory iNHL [Phase 3]
Phase III trial update for copanlisib in rituximab-refractory indolent non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis [Phase 2]
Phase 2 clinical trial update for 68GaNOTA-Anti-MMR-VHH2 imaging agent across multiple indications including solid malignancies of the head …
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 clinical trial of Fc-Optimized Anti-CD19 antibody MOR00208 in Non-Hodgkin Lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-03Clinical Trial Update: Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
A completed clinical trial evaluating cardiac magnetic resonance imaging in patients with non-Hodgkin lymphoma or Hodgkin lymphoma receiving…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating obinutuzumab, rituximab, polatuzumab vedotin, and venetoclax in relapsed/refractory follicular lympho…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of acalabrutinib with R-CHOP in patients with non-Hodgkin lymphoma (diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study [Phase 1, Phase 2]
Long-term follow-up update from BP-004 study (Phase 1/Phase 2) by Bellicum Pharmaceuticals; study status TERMINATED with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor [Phase 2]
Phase II trial evaluating safety and efficacy of subcutaneous plerixafor in related donors of peripheral blood stem cells for various hemato…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
This Phase 2 Pediatric MATCH trial evaluated vemurafenib in children with BRAF V600-mutant relapsed or refractory advanced solid tumors, non…
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial investigating a vaccine therapy plus sargramostim after chemotherapy in previously untreated aggressive non-Hodgkin's lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab with combination chemotherapy followed by transplantation in relapsed or refractory non-Hodgkin'…
-
CLINICAL_TRIALS trial_result · 2023-08-23Clinical Trial Update: Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma [Phase 4]
Phase 4 trial update on Zevalin followed by Rituxan maintenance in previously treated low-grade non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial updating on the use of entospletinib with obinutuzumab in relapsed CLL/SLL or NHL; Phase 1/2 study status completed with resu…
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation [Phase 2]
Phase 2 trial update on once-daily targeted IV busulfan as part of reduced-toxicity conditioning for patients with refractory lymphomas unde…
-
CLINICAL_TRIALS trial_result · 2023-07-12Clinical Trial Update: Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating a vaccine therapy to reduce cytomegalovirus events in patients with hematologic malignancies undergoing donor stem …
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL [Phase 1, Phase 2]
Clinical trial update for TRAC locus-inserted CD19-targeting STAR-T cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma (Phase 1…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning [Phase 2]
Phase 2 trial update on allogeneic transplantation using timed sequential busulfan and fludarabine conditioning for various hematologic mali…